Avelumab Plus Talazoparib in Patients with BRCA1/2 - Or ATM -Altered Advanced Solid Tumors: Results from JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial

Alison M. Schram, Nicoletta Colombo, Edward Arrowsmith, Vivek Narayan, Kan Yonemori, Giovanni Scambia, Amelia Zelnak, Todd M. Bauer, Ning Jin, Susanna V. Ulahannan, Marco Colleoni, Philippe Aftimos, Mark T.A. Donoghue, Ezra Rosen, Vasilisa A. Rudneva, Melinda L. Telli, Susan M. Domchek, Matthew D. Galsky, Margaret Hoyle, Colombe ChappeyRoss Stewart, John A. Blake-Haskins, Timothy A. Yap

Research output: Contribution to journal › Article › peer-review

19 Scopus citations

Fingerprint

Dive into the research topics of 'Avelumab Plus Talazoparib in Patients with BRCA1/2 - Or ATM -Altered Advanced Solid Tumors: Results from JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial'. Together they form a unique fingerprint.

Medicine & Life Sciences